arrow
R

Raburn M. Mallory

novavax inc., gaithersburg, maryland, usa
H指数:21
被引数:6,478

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19)

NVX-CoV2373四次序贯剂量的安全性与免疫原性:一项在成人和青少年中进行的3期、随机、安慰剂对照试验(PREVENT-19)

Vaccine
IF3.5
2025-07-080
OA
Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label study

一种单价奥密克戎XBB.1.5 SARS-CoV-2重组刺突蛋白疫苗在既往未接种疫苗、SARS-CoV-2血清阳性的受试者中的免疫原性和安全性:一项开放标签2/3期研究的第28天主要分析

VACCINE
IF3.5
2025-05-010
OAAI
Safety and immunogenicity of a single dose of a JN.1 variant COVID-19 vaccine in previously vaccinated adults: Primary analysis report of a phase 3 open-label trial

单剂量JN.1变异新型冠状病毒肺炎疫苗在先前接种过疫苗的成人中的安全性和免疫原性: 一项3期开放标签试验的初步分析报告

VACCINE
IF3.5
2025-02-010
OAAI
Safety and immunogenicity of Omicron protein vaccines in mRNA vaccinated adolescents: A phase 3, randomised trial-

奥密克戎蛋白疫苗在mRNA疫苗接种青少年中的安全性与免疫原性:一项III期随机试验

2025-02-010
OAAI
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial
2024-06-012
OAAI
Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial

异源Omicron BA.1和二价SARS-CoV-2重组刺突蛋白加强疫苗的免疫原性和安全性: 一项3期随机临床试验

2023-11-162
OAAI
Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India A Phase 2-3 Randomized Clinical Trial
2023-09-016
PRE
Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine

NVX-CoV2373疫苗的安全性、有效性和免疫原性

2023-06-0512
OA
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial
2022-11-0152
OAAI
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

ChAdOx1 nCoV-19疫苗 (AZD1222) 抗SARS-CoV-2的安全性和有效性: 对巴西、南非和英国的四项随机对照试验的中期分析

LANCET
IF88.5
2021-01-013.2K
OAAI